Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dragonfly Therapeutics
National Cancer Institute (NCI)
Bristol-Myers Squibb
Replimune Inc.
Bristol-Myers Squibb
Myeloid Therapeutics
Yale University
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
BicycleTx Limited
University of Texas Southwestern Medical Center
Nanobiotix
Maastricht University Medical Center
University of Kansas Medical Center
Dana-Farber Cancer Institute
Bolt Biotherapeutics, Inc.
Memgen, Inc.
Incyte Corporation
Bristol-Myers Squibb
Instituto do Cancer do Estado de São Paulo
Mayo Clinic
Washington University School of Medicine
Exelixis
Providence Health & Services
Daiichi Sankyo
Compugen Ltd
Bristol-Myers Squibb
Georgetown University
Eli Lilly and Company
Astellas Pharma Inc
Memorial Sloan Kettering Cancer Center
Oslo University Hospital
The Netherlands Cancer Institute
OHSU Knight Cancer Institute
Centre Leon Berard
Fondazione per la Medicina Personalizzata
Fate Therapeutics
Jonsson Comprehensive Cancer Center
Tempest Therapeutics
Fate Therapeutics
Nektar Therapeutics
Nektar Therapeutics
Jules Bordet Institute
Calithera Biosciences, Inc
Bristol-Myers Squibb
Incyte Corporation
Duke University
Infinity Pharmaceuticals, Inc.
The Netherlands Cancer Institute